Microbot Medical Launches Full Market Release of LIBERTY Robotic System After Successful Limited Rollout
Summary
Microbot Medical announced the successful completion of its limited market release and the commencement of the full market release for its LIBERTY Endovascular Robotic System in the U.S., with key hospital adoptions and an expanded sales team.
Key Events
-
Full Market Release Commenced
Microbot Medical has commenced the full market release of its LIBERTY Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting.
-
Successful Limited Market Release
The company successfully executed its limited market release, with the LIBERTY system adopted by multiple healthcare systems and used commercially across various endovascular procedures.
-
Key Hospital Adoptions
Globally recognized hospitals such as Emory Healthcare and Tampa General Hospital are among those that have adopted the LIBERTY system.
-
Expanded Commercial Footprint
Microbot Medical has enhanced its commercial team, broadening its sales footprint from four to eight territories, with a goal of 12 territories across the U.S. by the end of 2026.
Analysis
Microbot Medical's announcement of the full market release of its LIBERTY Endovascular Robotic System, following a successful limited market release, is a significant positive development. The adoption by multiple healthcare systems, including prominent hospitals like Emory Healthcare and Tampa General, demonstrates early commercial traction and validates the system's utility across various procedures. This operational progress, coupled with the expansion of their sales footprint, indicates a strategic push for growth and could help justify the recent At-The-Market offering initiated on April 10, 2026, by demonstrating a clear path for capital deployment towards commercial expansion.
At the time of this filing, MBOT was trading at $2.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $173.9M. The 52-week trading range was $1.48 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.